Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Cerus Corporation is a biomedical products company dedicated to safeguarding the world's blood supply. Their flagship product, the INTERCEPT Blood System, is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites in donated blood components (platelets, plasma, and red blood cells under investigation). Cerus focuses on providing solutions for blood centers and hospitals to enhance the safety and availability of blood transfusions for patients worldwide, with a mission to make blood transfusions the safest medical intervention.
Serves as the primary center for corporate leadership, research and development (R&D), strategic planning, global operations management, and administrative functions.
The Concord facility likely houses advanced research laboratories for biomedical product development, quality control, and testing, alongside modern office spaces designed to foster collaboration and innovation.
Cerus fosters a science-driven, mission-oriented work culture. Employees are typically passionate about public health, innovation in blood safety, and making a significant impact on patient care globally. The environment emphasizes collaboration, integrity, and a commitment to quality.
The Concord headquarters is crucial for Cerus's global strategy, driving innovation in its INTERCEPT Blood System technology, managing clinical trials, and overseeing the commercialization and distribution of its products worldwide.
Cerus Corporation has a significant global presence, with its INTERCEPT Blood System used by blood centers and hospitals in numerous countries. Key functions supported globally include sales and marketing, clinical support and education, product distribution, regulatory affairs, and post-market surveillance. While direct operations are prominent in North America and Europe, Cerus also works with a network of distributors to extend its reach to other regions, including Asia-Pacific and Latin America, aiming to make its blood safety technology a worldwide standard.
1220 Concord Avenue
Concord
California
USA
Address: Stationsplein 13 N, 3818 LE Amersfoort, Netherlands
To drive adoption of the INTERCEPT Blood System across the EMEA region, provide regional customer and technical support, and navigate local regulatory landscapes to ensure product availability.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cerus Corporation' leadership includes:
Cerus Corporation has been backed by several prominent investors over the years, including:
In the past 12 months, Cerus Corporation has made strategic adjustments to its financial leadership team, notably appointing a new Chief Accounting Officer.
Discover the tools Cerus Corporation uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cerus Corporation commonly uses email formats based on employee names, typically combining the first initial and last name. Variations might exist, but this is a frequently observed pattern.
[first_initial][last]@cerus.com
Format
jdoe@cerus.com
Example
90%
Success rate
Cerus Corporation Investor Relations • May 2, 2024
Cerus announced its financial results for the first quarter ended March 31, 2024, highlighting product revenue of $38.5 million and providing updates on its development pipeline, including the INTERCEPT Fibrinogen Complex and Red Blood Cell programs....more
Cerus Corporation Investor Relations • May 8, 2024
Cerus Corporation announced that its management team would present at the BofA Securities 2024 Health Care Conference on May 15, 2024, offering an overview of the company's business and strategic initiatives to the investment community....more
Cerus Corporation Investor Relations • March 12, 2024
Cerus announced it received U.S. Food and Drug Administration (FDA) approval for an Investigational Device Exemption (IDE) supplement. This allows the use of INTERCEPT-treated red blood cells prepared with a new, second-generation (E2) processing set in a Phase 3 clinical study (ReCePI) in Puerto Rico for chronically transfused sickle cell disease patients....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cerus Corporation, are just a search away.